Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
New Alzheimer's drug slows cognitive decline by 27%, clinical trial finds
11:02pm, Tuesday, 27'th Sep 2022
Lecanemab, a drug from Eisai and Biogen, was observed in a large-scale trial to have slowed the disease's progression by 27% over 18 months.
Alzheimer's drug from Eisai, Biogen shows promise in large trial
07:57pm, Tuesday, 27'th Sep 2022
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer's disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering th
Hurricane Ian to intensify, Biogen settles lawsuit, Ford asks for new trial after $1.7 billion loss
11:46am, Tuesday, 27'th Sep 2022
Yahoo Finance's Julie Hyman reports the latest notable business headlines including Hurricane Ian becoming a Category 4 hurricane before hitting Florida, Biogen settling a lawsuit that alleged the com
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs
07:08pm, Monday, 26'th Sep 2022
A former Biogen employee, Michael Bawduniak, alleged Biogen paid kickbacks to doctors to encourage them to prescribe its multiple sclerosis drugs.
Can We Beat Alzheimer's? Biogen's Latest Drug Trial Will Offer Clues.
04:00am, Thursday, 22'nd Sep 2022
Biogen is getting one more crack at Alzheimer's this fall. It's a critical moment for the company, which recently abandoned plans to sell Aduhelm, another drug targeting the disease, after Medicare ef
Tracking Southeastern Asset Management Portfolio - Q2 2022 Update
04:13am, Wednesday, 14'th Sep 2022 Seeking Alpha
Southeastern’s 13F portfolio value decreased from $5.66B to $4.74B this quarter. Click to read an update on the firm's holdings and trades for Q2 2022.
Expert Ratings for Biogen
07:09pm, Monday, 12'th Sep 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company'
Biogen Inc. (BIIB) Morgan Stanley 20th Annual Global Healthcare Conference Call (Transcript)
02:16pm, Monday, 12'th Sep 2022
Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 9:55 AM ET Company Participants Michael McDonnell - Chief Financial Officer Priya Singhal - H
This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?
01:07pm, Monday, 12'th Sep 2022 The Motley Fool
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
Best Stocks To Buy Now? 4 Biotech Stocks In Focus
12:10pm, Sunday, 11'th Sep 2022
Is now a good time to add these biotech stocks to your watchlist?
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
12:39pm, Friday, 09'th Sep 2022 Zacks Investment Research
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Is There Upside For Biogen Stock?
08:45am, Friday, 09'th Sep 2022
Biogen stock (NASDAQ: BIIB) has seen a 16% fall this year, in line with the broader S&P500 index, which is down 16%.
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
09:45pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published a second manuscript detailing positive
Give Me Those Obscene Profit Margins
10:38am, Tuesday, 06'th Sep 2022
The point of business is not revenue, or growth. It's profit.
2 Top Biotech Stocks to Buy Right Now
10:30am, Sunday, 04'th Sep 2022 The Motley Fool
They have what it takes to generate major revenue over the years to come.
